JUAN
PASQUAU LIAÑO
Forscher in der Zeit 2022-2023
Publikationen (103) Publikationen von JUAN PASQUAU LIAÑO
2024
-
DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain
Viruses, Vol. 16, Núm. 2
-
Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study
Journal of Global Antimicrobial Resistance, Vol. 36, pp. 200-209
-
Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe
Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159
2023
-
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
International Journal of Antimicrobial Agents, Vol. 62, Núm. 3
-
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Viruses, Vol. 15, Núm. 7
-
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis
Open Forum Infectious Diseases, Vol. 10, Núm. 11
2022
-
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Viruses, Vol. 14, Núm. 3
-
Dalbavancin in clinical practice in Spain: A 2 year retrospective study
JAC-Antimicrobial Resistance, Vol. 4, Núm. 6
-
Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections
Scientific Reports, Vol. 12, Núm. 1
-
Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
Viruses, Vol. 14, Núm. 12
-
Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program
Revista Espanola de Quimioterapia, Vol. 35, pp. 102-107
2021
-
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 9, pp. 1517-1525
-
Effectiveness of the quadrivalent hpv vaccine in preventing anal ≥ hsils in a spanish population of hiv+ msm aged > 26 years
Viruses, Vol. 13, Núm. 2
-
Recommendations for antibiotic selection for severe nosocomial infections
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 5, pp. 511-524
-
Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments
PLoS ONE, Vol. 16, Núm. 2 February
2020
-
Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial
Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305
-
Healthcare-associated pneumonia: a prospective study in Spain
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 33, Núm. 5, pp. 358-368
-
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524
-
Safety and Tolerability of More than Six Days of Tedizolid Treatment
Antimicrobial agents and chemotherapy, Vol. 64, Núm. 7
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1